这个研究暗示单一管理型的氯胺酮不论是对单极性还是双极性的抑郁症都能进行快速而有效的治疗。 英文版本拥有更多信息,请阅读下文。

通过订阅IDPC每月警报 随时掌握与药物政策发展相关的最新信息。

Interest has been growing in ketamine as a treatment of depression (Aan Het Rot, et al 2012; Diamond et al., 2014) and there is some genuine excitement among some of the elvish bloggers.

Mainly used in veterinary surgery, ketamine has been discovered to rapidly improve even the most severe cases of unipolar and bipolar depression. However, as yet there are still many questions left unanswered before ketamine can become a licensed treatment alternative.

For one, there needs to be more clarity about the safety and effectiveness of the drug before an informed weighing of pros and cons is feasible. In addition, in order to stay on top of the immense interest ketamine has spurred, it is essential to have an updated overview of all studies out there. To this end McGirr et al have provided the most recent systematic review of methodologically sound studies (McGirr et al, 2014).

Click here to read the full article.

Keep up-to-date with drug policy developments by subscribing to the IDPC Monthly Alert